These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31936239)

  • 1. Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer.
    Jin W
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31936239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling.
    Fan Y; Zhang B; Du X; Wang B; Yan Q; Guo L; Yao W
    Curr Cancer Drug Targets; 2024; 24(3):271-287. PubMed ID: 37670705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
    Tanaka H; Sase H; Tsukaguchi T; Hasegawa M; Tanimura H; Yoshida M; Sakata K; Fujii T; Tachibana Y; Takanashi K; Higashida A; Hasegawa K; Ono Y; Oikawa N; Mio T
    Mol Cancer Ther; 2018 Dec; 17(12):2519-2529. PubMed ID: 30242093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors.
    Sheng J; Chen H; Fu B; Pan H; Wang J; Han W
    NPJ Precis Oncol; 2024 Sep; 8(1):198. PubMed ID: 39256512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer.
    Kim MS; Jeong J; Seo J; Kim HS; Kim SJ; Jin W
    Sci Rep; 2016 Sep; 6():33899. PubMed ID: 27654855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
    Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
    Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting TRK Proteins in Clinical Cancer Therapy.
    Lange AM; Lo HW
    Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29617282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting TRK family proteins in cancer.
    Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
    Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
    Cocco E; Lee JE; Kannan S; Schram AM; Won HH; Shifman S; Kulick A; Baldino L; Toska E; Arruabarrena-Aristorena A; Kittane S; Wu F; Cai Y; Arena S; Mussolin B; Kannan R; Vasan N; Gorelick AN; Berger MF; Novoplansky O; Jagadeeshan S; Liao Y; Rix U; Misale S; Taylor BS; Bardelli A; Hechtman JF; Hyman DM; Elkabets M; de Stanchina E; Verma CS; Ventura A; Drilon A; Scaltriti M
    Cancer Discov; 2021 Jan; 11(1):126-141. PubMed ID: 33004339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.
    Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
    Expert Opin Ther Pat; 2017 Jul; 27(7):831-849. PubMed ID: 28270021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
    Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
    Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in tyrosine kinase receptor (Trk) expression induced by insulin-like growth factor-1 in cultured dorsal root ganglion neurons.
    Li H; Zhang P; Fu G; Li J; Liu H; Li Z
    Brain Res Bull; 2013 Jan; 90():25-34. PubMed ID: 23022575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
    Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
    Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 15. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.
    Tognon C; Garnett M; Kenward E; Kay R; Morrison K; Sorensen PH
    Cancer Res; 2001 Dec; 61(24):8909-16. PubMed ID: 11751416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TrkC promotes colorectal cancer growth and metastasis.
    Kim MS; Suh KW; Hong S; Jin W
    Oncotarget; 2017 Jun; 8(25):41319-41333. PubMed ID: 28455963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TrkC plays an essential role in breast tumor growth and metastasis.
    Jin W; Kim GM; Kim MS; Lim MH; Yun C; Jeong J; Nam JS; Kim SJ
    Carcinogenesis; 2010 Nov; 31(11):1939-47. PubMed ID: 20802235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotrophin Trk Receptors: New Targets for Cancer Therapy.
    Meldolesi J
    Rev Physiol Biochem Pharmacol; 2018; 174():67-79. PubMed ID: 28884193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression of TrkC (NTRK3) in human soft tissue tumours.
    Hisaoka M; Sheng WQ; Tanaka A; Hashimoto H
    J Pathol; 2002 Aug; 197(5):661-7. PubMed ID: 12210087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.